Skip to main content
Premium Trial:

Request an Annual Quote

Newtopia Inks Aetna Contract for Metabolic Syndrome Personalized Med Program

NEW YORK (GenomeWeb) – Following a pilot study, Newtopia has signed a contract to provide Aetna's customers with a personalized health program that utilizes genetic testing and behavioral science targeted at those with metabolic syndrome.

The Toronto-based firm had previously provided such services to around 500 Aetna employees under a pilot program designed to gauge if Newtopia's genetic testing and coaching program could reduce their risk of metabolic syndromes over the period of a year. According to Newtopia, Aetna verified that employees enrolled in the program "lost weight, reduced their waist size, and had high levels of engagement in the program."

Terms of the new contract were not disclosed.

"As we continue to work towards improving health outcomes and reducing healthcare costs for our members, Newtopia provides an opportunity for individuals to be inspired by a health engagement platform that allows them to develop healthy habits to meet their own unique lifestyles," Greg Steinberg, head of clinical innovation at Aetna, said in a statement.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.